Relevant research has demonstrated that MEP may activate the MAPK3 pathway, leading to an increased production and release of inflammatory mediators, thereby exacerbating neuronal damage and accelerating the pathological progression of AD. This evidence concerns the gene MAPK3 and Alzheimer disease.